
Abiraterone Acetate Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 250 mg, 500 mg
Reference Brands: Zytiga®(EU & US)
Category: Oncology Cancer Care
Abiraterone Acetate is available in Tablet and strengths such as 250 mg, 500 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Abiraterone Acetate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
Technical Specifications & Supply Details | |
---|---|
Lead Time | 7 to 60 days (depending on batch size & schedule) |
MOQ | As per manufacturer’s batch size |
COA | Available with every batch |
Regulatory Dossier / DMF | Available upon request |
Export Documentation | FSC, COA, Manufacturing License, Product Permission |
Standards | IP, BP, USP |
Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Abiraterone Acetate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Abiraterone Acetate Tablets, available in 250 mg and 500 mg strengths, are a key oral oncology product used in treating metastatic prostate cancer. Approved across the U.S. and EU, Abiraterone inhibits androgen biosynthesis by targeting the CYP17 enzyme, effectively suppressing tumor growth in hormone-sensitive prostate cancers. Marketed under the brand name Zytiga® and widely available as generics, this therapy is often used alongside prednisone. Abiraterone Acetate is a vital product for pharma B2B oncology portfolios, offering significant therapeutic benefit and global demand in both hospital and retail oncology markets.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsDurvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View DetailsSunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers